XML 73 R26.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2024
Income Taxes  
Schedule of components of the gross deferred tax asset and related valuation allowance

    

2024

    

2023

 

Deferred income tax assets:

Net operating loss carryforward

$

96,811,786

$

88,746,869

Research and orphan drug credits

 

54,937,994

 

53,152,849

Capitalized research costs

 

11,861,613

 

10,748,355

Capitalized start-up costs

 

339,138

 

532,931

Patent amortization

 

27,071

 

42,541

Stock-based compensation

 

6,699,628

 

7,324,617

Accrued bonus

25,356

704,974

Operating lease liabilities

18,394

222,452

Other

1,303

87,097

Gross deferred income tax assets

 

170,722,283

 

161,562,685

Valuation allowance

 

(170,722,283)

 

(161,351,398)

Net deferred income tax assets

 

 

211,287

Deferred income tax liabilities:

Operating lease right-of-use assets

 

 

(211,287)

Gross deferred income tax liabilities

 

 

(211,287)

Net deferred income tax asset/(liability)

$

$

Schedule of reconciliations between the statutory federal income tax rate and the effective income tax rate of income tax expense

    

2024

    

2023

    

U.S. Federal statutory tax rate

 

21.0

%  

21.0

%  

State taxes

 

5.9

 

6.3

 

Research credit

 

0.4

 

0.7

 

Orphan drug credit

 

4.1

 

4.1

 

Stock-based compensation

(5.1)

2.3

Executive compensation

(1.2)

(0.1)

Other

(0.4)

(3.5)

Change in valuation allowance

 

(24.7)

 

(30.8)

 

Provision for income taxes

 

%

%